High-Dose Chemotherapy and Autologous Stem Cell Transplantation in Children with High-Risk or Recurrent Bone and Soft Tissue Sarcomas.
10.3346/jkms.2016.31.7.1055
- Author:
Young Bae CHOI
1
;
Eun Sang YI
;
Ji Won LEE
;
Keon Hee YOO
;
Ki Woong SUNG
;
Hong Hoe KOO
Author Information
1. Department of Pediatrics, Chung-Ang University Hospital, Seoul, Korea.
- Publication Type:Case Reports
- Keywords:
Bone and Soft Tissue Sarcoma;
Children;
High-Dose Chemotherapy;
Autologous Stem Cell Transplantation
- MeSH:
Adolescent;
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use;
Bone Neoplasms/mortality/pathology/*therapy;
Child;
Child, Preschool;
Disease-Free Survival;
Female;
Follow-Up Studies;
Humans;
Infant;
Male;
Retrospective Studies;
Sarcoma/mortality/pathology/*therapy;
Soft Tissue Neoplasms/mortality/pathology/*therapy;
*Stem Cell Transplantation;
Survival Rate;
Transplantation, Autologous;
Treatment Outcome;
Young Adult
- From:Journal of Korean Medical Science
2016;31(7):1055-1062
- CountryRepublic of Korea
- Language:English
-
Abstract:
Despite increasing evidence that high-dose chemotherapy and autologous stem cell transplantation (HDCT/auto-SCT) might improve the survival of patients with high-risk or recurrent solid tumors, therapy effectiveness for bone and soft tissue sarcoma treatment remains unclear. This study retrospectively investigated the feasibility and effectiveness of HDCT/auto-SCT for high-risk or recurrent bone and soft tissue sarcoma. A total of 28 patients (18 high-risk and 10 recurrent) underwent single or tandem HDCT/auto-SCT between October 2004 and September 2014. During follow-up of a median 15.3 months, 18 patients exhibited disease progression and 2 died of treatment-related toxicities (1 veno-occlusive disease and 1 sepsis). Overall, 8 patients remained alive and progression-free. The 3-year overall survival (OS) and event-free survival (EFS) rates for all 28 patients were 28.7% and 26.3%, respectively. In the subgroup analysis, OS and EFS rates were higher in patients with complete or partial remission prior to HDCT/auto-SCT than in those with worse responses (OS, 39.1% vs. 0.0%, P = 0.002; EFS, 36.8% vs. 0.0%, P < 0.001). Therefore, careful selection of patients who can benefit from HDCT/auto-SCT and maximal effort to reduce tumor burden prior to treatment will be important to achieve favorable outcomes in patients with high-risk or recurrent bone and soft tissue sarcomas.
